Navigation Links
Boehringer Ingelheim Presents New Phase II Data for Volasertib in Adult Patients with AML
Date:12/10/2012

9–158) days and 64 (30–125) days, respectively.1

Secondary endpoints included event-free survival (EFS), overall survival (OS) and safety.  EFS was measured from the date of randomization to the date of disease progression (treatment failure), relapse or death from any cause, whichever occurred first.  In patients treated with the combination of volasertib plus LDAC, the median EFS was approximately 5.6 months (170 days) compared with approximately 2.3 months (69 days) in patients treated with LDAC alone (hazard ratio: 0.56; 95% CI: 0.34, 0.93; p=0.0237).  Follow-up for overall survival was ongoing at the time of this analysis.1   

"The preliminary results from this trial provide insight into the potential of volasertib combined with LDAC in patients with AML not eligible for intensive induction chemotherapy," said Berthold Greifenberg, M.D., vice president, Clinical Development and Medical Affairs, Oncology, Boehringer Ingelheim Pharmaceuticals, Inc.  "Based on the results observed in this difficult-to-treat patient population, we are expanding our volasertib hematology clinical program to further explore this investigational compound." 

In the volasertib plus LDAC treatment arm (n=42), grade 5 non-hematologic adverse events (AEs) were infections (5%), febrile neutropenia (5%) and respiratory/thoracic/mediastinal events (7%).  Grade 3/4 non-hematologic AEs were gastrointestinal events (19/2%), general events (14/2%), infections (38/5%), febrile neutropenia (38/7%), metabolism/nutrition events (10/5%) and respiratory/thoracic/mediastinal events (14/2%).  In the LDAC monotherapy arm (n=45), grade 5 non-hematologic AEs were infections (9%), and grade 3/4 non-hematologic AEs were gastrointestinal events (7/0%), general events (16/2%), infections (7/7%), febrile neutropenia (4/9%), metabolism/nutrition events (7/0%) and respiratory/thoracic/mediastinal events (11/2%
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boehringer Ingelheim Announces Equine Research Awards
2. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
3. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
4. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
5. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
8. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
9. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
10. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
11. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... 2015  BioMed Realty Trust, Inc. (NYSE: ... square feet of space in the most dynamic and ... through the termination of Vertex Pharmaceuticals, leases on three ... February 28, 2015. BioMed Realty will receive a $14 ... to reposition the properties to meet the growing demand ...
(Date:3/1/2015)... 2, 2015 LifeScienceIndustryResearch.com announces ... Report of 178 pages along with 8 company ... The 2015 Market Research Report on ... and deep research report on Global Angiographic X-ray ... Angiographic X-ray System basic information including definition, classification, ...
(Date:3/1/2015)... 2015  Patients suffering from chronic plantar fasciitis ... foot ailment, according to research presented at the ... Scientific Meeting . Researchers utilized ultrasound imaging and ... diseased fasciitis tissue. Permanently removing damaged, pain-generating tissue ... its place, restoring normal function. "Plantar ...
Breaking Medicine Technology:BioMed Realty Gets Back 313,000 Square Feet Of Valuable Real Estate In Cambridge Innovation District 2BioMed Realty Gets Back 313,000 Square Feet Of Valuable Real Estate In Cambridge Innovation District 3Global Angiographic X-ray System Industry Research Report 2Global Angiographic X-ray System Industry Research Report 3Global Angiographic X-ray System Industry Research Report 4Global Angiographic X-ray System Industry Research Report 5Interventional radiology treatment relieves chronic plantar fasciitis 2Interventional radiology treatment relieves chronic plantar fasciitis 3
(Date:3/2/2015)... (PRWEB) March 02, 2015 In light ... of anticoagulant Xarelto (rivaroxaban) tablets, Ford & ... may be helpful for future users, but may come ... injuries from taking the drug. The FDA has now ... under Adverse Reactions on Xarelto's label. The term “cytolytic ...
(Date:3/2/2015)... March 02, 2015 ProvidaStaff ... for its educational healthcare division to EDU Healthcare ... healthcare services to school systems and students nationwide. , ... to school districts throughout the country,” said Angela M. ... be a better organization and the introduction of EDU ...
(Date:3/1/2015)... To help healthcare organizations ... practices compliantly and profitably, MDreferralPRO and Vericle ... The interoperability between a strategic referral management ... management system is necessary for a healthcare ... referral management and development solution relies on ...
(Date:3/1/2015)... 2015 Women’s Excellence now offers ... (OAB) symptoms, such as a strong need to urinate with ... medication (anticholinergic) does not work well enough or cannot be ... another approach to targeting the source of OAB, the bladder ... and bladder muscle, blocking the signals that trigger OAB. ...
(Date:3/1/2015)... March 01, 2015 A federal ... http://www.consumerinjurylawyers.com/wright-profemur-hip-replacement ) scheduled to go to trial in ... a witness to provide testimony regarding the role ... of the Profemur device, Bernstein Liebhard LLP comments. ... Court, Northern District of Iowa on February 25th, ...
Breaking Medicine News(10 mins):Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 2Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 3Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 4Health News:ProvidaStaff Announces New Name Change to EDU Healthcare for Its Educational Healthcare Division 2Health News:ProvidaStaff Announces New Name Change to EDU Healthcare for Its Educational Healthcare Division 3Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 2Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 3Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 4Health News:Women's Excellence Now Offers BOTOX For Overactive Bladder Treatment 2Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 2Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 3
... may help reduce unnecessary surgeries in women of reproductive ... study appearing in the February issue of the journal ... of preoperative CT over the past decade, along with ... in negative appendectomies among women 45 years and younger," ...
... WASHINGTON , Jan. 25 Detroit -area ... in a Detroit -area home health care fraud scheme, announced ... U.S. Attorney for the Eastern District of Michigan Barbara L. McQuade; ... Field Office; and Special Agent in Charge Lamont Pugh III of ...
... , , "Was John Brown,s raid on Harpers ... a hero or a villain?" Randall Terry , WICHITA, ... by Randall Terry , Director, Operation Rescue Insurrecta Nex. , Statement ... or condemn Scott Roeder,s actions. That decision will soon rest ...
... "America,s health care problems did not change when the ... need Congress to act on Health Care Reform now", insists Dr. ... focus on the economy and jobs is necessary and proper, however ... health care reform will bring to all Americans.   We must ...
... , Jan. 25 January is almost over and ... spirit of the Holidays, the Phoenix Quest Center is offering the ... development.  This course is a great opportunity to help participants start ... as offering them valuable skills in dealing with social conflicts of ...
... , PHILADELPHIA , Jan. 25 ... defects in humans, affecting 8 per 1000 live births ... early infancy. Increasing numbers of survivors combined with developmental ... led to a growing identification of neurobehavioral symptoms in ...
Cached Medicine News:Health News:Preoperative CT useful for younger women with suspected appendicitis 2Health News:Physical Therapist Pleads Guilty in Connection with Detroit Home Health Care Fraud Scheme 2Health News:Physical Therapist Pleads Guilty in Connection with Detroit Home Health Care Fraud Scheme 3Health News:Scott Roeder Trial: Randall Terry, Operation Rescue Founder and Insurrecta Nex Members to Attend Trial in Wichita 2Health News:National Medical Association Urges Congress to Deliver on Health Care 2Health News:60-Day Free Community Confidence Building and Self-Defense Training 2Health News:Special Bypass Procedure Used During Infant Heart Surgery Does Not Impair Later Neurological Outcomes in Children 2Health News:Special Bypass Procedure Used During Infant Heart Surgery Does Not Impair Later Neurological Outcomes in Children 3
Created to simplify stereopsis screening in children. Based on principles of random dots. No glasses are necessary for this stereo test, and the child's eye movement can be easily observed....
... versatile new test providing the broadest range ... The Multi-Target Stereo test can be used ... stereopsis, visual attention, form and depth perception, ... includes a pair of high quality reversible ...
... These polarized stereo tests provide ... come with a choice of polarized ... thick film lenses slipped into a ... The other choice includes Richmonds new ...
Comes with seven test plates. Red and green glasses filters are mounted in two frames, one for adults and one for children. Suitable for testing very small children as well as adults....
Medicine Products: